Table 2.
The baseline characters of the included studies.
| Study | Country | Participant | AF sample size | Prevalence of AF (%) | Study design | Female | Age range/mean age (yrs) |
|---|---|---|---|---|---|---|---|
| Uchôa 2015 | Brazil | 67 | 10 | 14.92537313 | Prospective study | 25% | 58 ± 8 |
| feng2019 | US | 506,604 | 183,075 | 36.13769335 | Retrospective cohort study | 31.80% | 66.2 ± 12.1 |
| gali2020 | US | 8612 | 2502 | 29.0524849 | Retrospective cohort study | 34.50% | 62.9 ± 13.8 |
| wong2015 | US | 545 | 226 | 41.46788991 | Retrospective cohort study | 13.21% | 66.15 |
| zhao2015 | Singapore | 160 | 35 | 21.875 | Prospective study | NR | 62.8 |
| chilukuri2009 | US | 210 | 45 | 21.42857143 | Prospective study | 20% | 58 ± 10 |
| chilukuri2010 | US | 109 | 34 | 31.19266055 | Prospective study | 21% | 60 ± 10 |
| jongnarangsin2008 | US | 324 | 127 | 39.19753086 | Prospective study | 24% | 57 ± 11 |
| neilan2013 | US | 720 | 720 | 100 | Retrospective cohort study | NR | NR |
| gami2007 | US | 3542 | 133 | 3.754940711 | Retrospective cohort study | 44% | 49 ± 14 |
| mehra2006 | US | 566 | 566 | 100 | Retrospective cohort study | NR | 69.4 |
| Mehra 2009 | US | 2911 | 138 | 4.740638956 | Cohort study | NR | 76.4 ± 5.4 |
| Selim 2016 | US | 697 | 38 | 5.451936872 | Cross-sectional analysis | 5.46% | 58.69 |
| Kendzerska 2018 | Canada | 8256 | 173 | 2.095445736 | Prospective study | 28% | 47 |
| Cadby 2015 | Australia | 6841 | 455 | 6.651074404 | Prospective study | 23% | 48.3 ± 12.5 |
| anzai2020 | US | 709 | 39 | 5.500705219 | Cross-sectional study | 0 | 83.2 ± 3.1 |